Recent advances in the treatment of sarcomas in gynecology
Uterine sarcomas are a heterologous group of rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognoses. Management of uterine sarcomas including leiomyosarcoma and endometrial stromal sarcoma are reviewed here, with additional...
Gespeichert in:
| Veröffentlicht in: | Discovery medicine 2014-09, Vol.18 (98), p.133-140 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 140 |
|---|---|
| container_issue | 98 |
| container_start_page | 133 |
| container_title | Discovery medicine |
| container_volume | 18 |
| creator | Lange, Sara S Novetsky, Akiva P Powell, Matthew A |
| description | Uterine sarcomas are a heterologous group of rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognoses. Management of uterine sarcomas including leiomyosarcoma and endometrial stromal sarcoma are reviewed here, with additional discussions regarding high-grade undifferentiated sarcoma and adenosarcoma. Uterine carcinosarcomas are currently staged and treated similar to high-grade epithelial endometrial carcinomas, thus will not be discussed in this review. Gemcitabine/docetaxel with adriamycin holds promise for the treatment of leiomyosarcoma, but currently, limited advancements have been made in discovering targeted therapies to these tumors. Continued translational research in both medical oncology and gynecologic oncology is necessary to forward the development of novel and targeted therapeutic agents in the treatment of sarcoma. Enrollment of these patients in clinical trials is encouraged, and will allow for the development of safer and more effective therapies. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1563059189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1563059189</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-a78ca98fcba4f38814e5d3fda46c31e4252c4feafd64bbb72baeea97f80e39ff3</originalsourceid><addsrcrecordid>eNo1j01LxDAURYMgzjj6F6RLN4WmSZrEnQx-wYAgui4vyctYaZrapEL_vaOOq7s4h8u9J2RNNeel1KxakfOUPqqKKabEGVnVoq6lFHxNbl7Q4pALcF8wWExFNxT5HYs8IeTwQ6IvEkw2BviF-2VAG_u4Xy7IqYc-4eUxN-Tt_u51-1junh-etre7cqwpzSVIZUErbw1wz5SiHIVj3gFvLKPID1ss9wjeNdwYI2sDiKClVxUy7T3bkOu_3nGKnzOm3IYuWex7GDDOqaWiYZXQVOmDenVUZxPQtePUBZiW9v8v-wakKVF8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1563059189</pqid></control><display><type>article</type><title>Recent advances in the treatment of sarcomas in gynecology</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lange, Sara S ; Novetsky, Akiva P ; Powell, Matthew A</creator><creatorcontrib>Lange, Sara S ; Novetsky, Akiva P ; Powell, Matthew A</creatorcontrib><description>Uterine sarcomas are a heterologous group of rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognoses. Management of uterine sarcomas including leiomyosarcoma and endometrial stromal sarcoma are reviewed here, with additional discussions regarding high-grade undifferentiated sarcoma and adenosarcoma. Uterine carcinosarcomas are currently staged and treated similar to high-grade epithelial endometrial carcinomas, thus will not be discussed in this review. Gemcitabine/docetaxel with adriamycin holds promise for the treatment of leiomyosarcoma, but currently, limited advancements have been made in discovering targeted therapies to these tumors. Continued translational research in both medical oncology and gynecologic oncology is necessary to forward the development of novel and targeted therapeutic agents in the treatment of sarcoma. Enrollment of these patients in clinical trials is encouraged, and will allow for the development of safer and more effective therapies.</description><identifier>EISSN: 1944-7930</identifier><identifier>PMID: 25227754</identifier><language>eng</language><publisher>United States</publisher><subject>Adenosarcoma - pathology ; Adenosarcoma - therapy ; Chemotherapy, Adjuvant ; Clinical Trials as Topic ; Combined Modality Therapy ; Endometrial Neoplasms - pathology ; Endometrial Neoplasms - therapy ; Female ; Humans ; Leiomyosarcoma - pathology ; Leiomyosarcoma - therapy ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Sarcoma - metabolism ; Sarcoma - pathology ; Sarcoma - therapy ; Sarcoma, Endometrial Stromal - pathology ; Sarcoma, Endometrial Stromal - therapy ; Translational Medical Research ; Uterine Neoplasms - metabolism ; Uterine Neoplasms - pathology ; Uterine Neoplasms - therapy</subject><ispartof>Discovery medicine, 2014-09, Vol.18 (98), p.133-140</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25227754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lange, Sara S</creatorcontrib><creatorcontrib>Novetsky, Akiva P</creatorcontrib><creatorcontrib>Powell, Matthew A</creatorcontrib><title>Recent advances in the treatment of sarcomas in gynecology</title><title>Discovery medicine</title><addtitle>Discov Med</addtitle><description>Uterine sarcomas are a heterologous group of rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognoses. Management of uterine sarcomas including leiomyosarcoma and endometrial stromal sarcoma are reviewed here, with additional discussions regarding high-grade undifferentiated sarcoma and adenosarcoma. Uterine carcinosarcomas are currently staged and treated similar to high-grade epithelial endometrial carcinomas, thus will not be discussed in this review. Gemcitabine/docetaxel with adriamycin holds promise for the treatment of leiomyosarcoma, but currently, limited advancements have been made in discovering targeted therapies to these tumors. Continued translational research in both medical oncology and gynecologic oncology is necessary to forward the development of novel and targeted therapeutic agents in the treatment of sarcoma. Enrollment of these patients in clinical trials is encouraged, and will allow for the development of safer and more effective therapies.</description><subject>Adenosarcoma - pathology</subject><subject>Adenosarcoma - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrial Neoplasms - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Leiomyosarcoma - pathology</subject><subject>Leiomyosarcoma - therapy</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Sarcoma - metabolism</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - therapy</subject><subject>Sarcoma, Endometrial Stromal - pathology</subject><subject>Sarcoma, Endometrial Stromal - therapy</subject><subject>Translational Medical Research</subject><subject>Uterine Neoplasms - metabolism</subject><subject>Uterine Neoplasms - pathology</subject><subject>Uterine Neoplasms - therapy</subject><issn>1944-7930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAURYMgzjj6F6RLN4WmSZrEnQx-wYAgui4vyctYaZrapEL_vaOOq7s4h8u9J2RNNeel1KxakfOUPqqKKabEGVnVoq6lFHxNbl7Q4pALcF8wWExFNxT5HYs8IeTwQ6IvEkw2BviF-2VAG_u4Xy7IqYc-4eUxN-Tt_u51-1junh-etre7cqwpzSVIZUErbw1wz5SiHIVj3gFvLKPID1ss9wjeNdwYI2sDiKClVxUy7T3bkOu_3nGKnzOm3IYuWex7GDDOqaWiYZXQVOmDenVUZxPQtePUBZiW9v8v-wakKVF8</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Lange, Sara S</creator><creator>Novetsky, Akiva P</creator><creator>Powell, Matthew A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Recent advances in the treatment of sarcomas in gynecology</title><author>Lange, Sara S ; Novetsky, Akiva P ; Powell, Matthew A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-a78ca98fcba4f38814e5d3fda46c31e4252c4feafd64bbb72baeea97f80e39ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenosarcoma - pathology</topic><topic>Adenosarcoma - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrial Neoplasms - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Leiomyosarcoma - pathology</topic><topic>Leiomyosarcoma - therapy</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Sarcoma - metabolism</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - therapy</topic><topic>Sarcoma, Endometrial Stromal - pathology</topic><topic>Sarcoma, Endometrial Stromal - therapy</topic><topic>Translational Medical Research</topic><topic>Uterine Neoplasms - metabolism</topic><topic>Uterine Neoplasms - pathology</topic><topic>Uterine Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lange, Sara S</creatorcontrib><creatorcontrib>Novetsky, Akiva P</creatorcontrib><creatorcontrib>Powell, Matthew A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Discovery medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lange, Sara S</au><au>Novetsky, Akiva P</au><au>Powell, Matthew A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent advances in the treatment of sarcomas in gynecology</atitle><jtitle>Discovery medicine</jtitle><addtitle>Discov Med</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>18</volume><issue>98</issue><spage>133</spage><epage>140</epage><pages>133-140</pages><eissn>1944-7930</eissn><abstract>Uterine sarcomas are a heterologous group of rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognoses. Management of uterine sarcomas including leiomyosarcoma and endometrial stromal sarcoma are reviewed here, with additional discussions regarding high-grade undifferentiated sarcoma and adenosarcoma. Uterine carcinosarcomas are currently staged and treated similar to high-grade epithelial endometrial carcinomas, thus will not be discussed in this review. Gemcitabine/docetaxel with adriamycin holds promise for the treatment of leiomyosarcoma, but currently, limited advancements have been made in discovering targeted therapies to these tumors. Continued translational research in both medical oncology and gynecologic oncology is necessary to forward the development of novel and targeted therapeutic agents in the treatment of sarcoma. Enrollment of these patients in clinical trials is encouraged, and will allow for the development of safer and more effective therapies.</abstract><cop>United States</cop><pmid>25227754</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1944-7930 |
| ispartof | Discovery medicine, 2014-09, Vol.18 (98), p.133-140 |
| issn | 1944-7930 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1563059189 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adenosarcoma - pathology Adenosarcoma - therapy Chemotherapy, Adjuvant Clinical Trials as Topic Combined Modality Therapy Endometrial Neoplasms - pathology Endometrial Neoplasms - therapy Female Humans Leiomyosarcoma - pathology Leiomyosarcoma - therapy Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Sarcoma - metabolism Sarcoma - pathology Sarcoma - therapy Sarcoma, Endometrial Stromal - pathology Sarcoma, Endometrial Stromal - therapy Translational Medical Research Uterine Neoplasms - metabolism Uterine Neoplasms - pathology Uterine Neoplasms - therapy |
| title | Recent advances in the treatment of sarcomas in gynecology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T01%3A23%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20advances%20in%20the%20treatment%20of%20sarcomas%20in%20gynecology&rft.jtitle=Discovery%20medicine&rft.au=Lange,%20Sara%20S&rft.date=2014-09-01&rft.volume=18&rft.issue=98&rft.spage=133&rft.epage=140&rft.pages=133-140&rft.eissn=1944-7930&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1563059189%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1563059189&rft_id=info:pmid/25227754&rfr_iscdi=true |